Executive summary Asthma is responsible for considerable global morbidity and health-care
costs. Substantial progress was made against key outcomes such as hospital admissions …

Context Asthma is readily diagnosed in most cases and usually responds to inhaled
corticosteroids with or without long-acting β agonists, theophyllines, or leukotriene-receptor …

The 2023 GINA Global Strategy report was updated with new information and guidance on
managing asthma. Some of the key changes include a clarification of terminology for asthma …

Asthma is a substantial health problem among children and adults worldwide, with high and
increasing prevalence rates., in many countries,' a substantial morbidity-reflected in hospital …

Until 2023, guidelines focused on asthma control as the primary goal of asthma treatment, 1
with the step-wise addition of drugs until the best possible disease control was achieved …

Drugs available for asthma treatment in the first decades of the 20th century
(sympathomimetic agents such as oral ephedrine, intravenous adrenaline, or inhaled …

Guidelines for asthma management focus on the use of combination inhaled treatment with
corticosteroids and longacting β-agonists for symptomatic asthma. In more severe disease …

There has been a recent increase in the prevalence of asthma worldwide; however, the 5–
10% of patients with severe disease account for a substantial proportion of the health costs …

Background Asthma is a common chronic airway disease worldwide. Despite its large
population size, China has had no comprehensive study of the national prevalence, risk …

The Global Asthma Report 2018 The Global Asthma Report 2018 Login University Home →
Library The Global Asthma Report 2018 Global Asthma Network ; Asher, Innes ; Ellwood …